Supplemental Materials of FY9/24 3Q
Consolidated Financial Results
August 8, 2024
Fuji Pharma Co., Ltd.

TSE:PRIME4554

FY9/24 3Q Consolidated Financial Summary➢ Net sales• Increased by 12.5% (+JPY 3.7 billion) in YoY due to increase of Women’s Healthcare
products, New products, positive revision of drug prices due to repricing NHI drug
price for unprofitable products and other factors.

➢ Operating Profit• Decreased by 7.8% (▲JPY 188 million) in YoY due to increase of R&D expenses andstrengthen sales structure.
➢ Development milestone payment for FSN-013 a dysmenorrhea treatment drugs
which has filed an application for approval.
➢ Exclusive negotiation rights for development and marketing of PH-80 a nextgeneration menopausal treatment drugs in Japan.
➢ Expenses for establishing a sales structure for “Ustekinumab BS SC Injection45mg”, which is scheduled to be listed on the NHI drug price list in May 2024.

➢ Net Income• Consolidated net income increased by 147.7% (+JPY 2.9 billion) in YoY due to therecording of special income from the sale of investment securities and other factors
in 1H.
2

FY9/24 3Q Consolidated Financial Results and Full Year Financial forecast Summary(¥million)

Net Sales

FY9/24 1Q-3Q

Full Year

FY9/23
Actual

FY9/24
ActualForecast

29,48233,155YoY（Ratio）+3,673※1

46,060(12.5%)EBITDAR

6,662

7,159+497

11,252(7.5%)（※2）

OperatingProfit2,403

Net Income

1,982

2,215

▲188

3,990

(▲7.8%)

4,910+2,9286,185(147.7%)※1：Based on “Notice Regarding Differences between Second Quarter Earnings Forecast and Actual Results and Partial Revision of Full-Year Earnings
Forecast” dated May 9, 2024
※2：EBITDAR＝An indicator of cash generation from core business（ Operating profit＋Depreciation (Including Leased Equipment)+R&D Expenses ）3

FY9/24 Consolidated Financial forecast➢ Net Sales• 3Q sales were as planned. In 4Q, sales of major Women’s Healthcare products andnew products (4 items) increased, 2H and full-year sales will be as planned.
• Sales of Ustekinumab BS is progressing ahead of plan.

➢ Operating Profit• In 4Q, new products sales will contribute, while costs are expected to rise. However,
SG&A expenses including R&D expenses will be suppressed, 2H and full-year sales willbe as planned.

➢ Net Income• Full-year net income is expected to increase by 80.1% (+JPY 2.8 billion) in YoY , asoriginally planned.

4FY9/24 3Q Consolidated financial results Forecast

FY9/24
ActualFirst halfForecast

Net Sales

21,388FY9/24
3Q
11,767

EBITDAR

4,716

2,443

4,093

11,252

Operating
Profit

1,443

772

1,775

3,990

Net Income

4,257

653

1,275

6,185

(¥million)

FY9/24
Forecast※1
4Q
12,90546,060（※2）※1：Based on “Notice Regarding Differences between Second Quarter Earnings Forecast and Actual Results and Partial Revision of Full-Year Earnings
Forecast” dated May 9, 2024
※2：EBITDAR＝An indicator of cash generation from core business（ Operating profit＋Depreciation (Including Leased Equipment)+R&D Expenses ）5

Sales by Field

6

Women’s Healthcare

7

Acute Medical Care

8

Appendix

Summary of FY9/24 3Q Consolidated Financial Results

10Sales of Top 15 Products

11IR Activity Summary
Number of interviews with institutional investors and analysts(for each of our accounting periods)
80706050794030522010222525

FY9/2019

FY9/2020

FY9/2021

310
FY9/2022

FY9/2023

FY9/2024⚫ Points that investors are paying attention to Our focus on field specialization remains unchanged, and we areshifting from a focus on generics to a high-value-added model
centered on new drugs and biosimilars.
 Future outlook and growth drivers in the women’s healthcare field Progress and future development of biosimilar business
12Note on forecast and prospects
The financial forecasts and other projections provided in this presentation are based on information available atthe time of its compilation and it therefore contains an element of uncertainty and potential risks.

Actual results may differ significantly from these forecasts for a number of reasons.
It should also be noted that the views and/or facts presented here may be altered or deleted without priornotification.
Information in this presentation about pharmaceuticals (including items in the pipeline) is not provided for thepurpose of marketing or advertising or of supplying medical advice.
Contact Information
Fuji Pharma Co., Ltd.
Corporate Planning Section
Corporate Planning Department
Corporate Strategy Division
E - M a i l : fsk_ir@fujipharma.jp
U R L : https://www.fujipharma.jp/